 |
BioWorld-International-2009-10-28
Genmab Gets Accelerated OK for Arzerra in Refractory CLL
Genmab Gets Accelerated OK for Arzerra in Refractory CLL
Genmab A/S passed its most significant milestone to date by obtaining its first drug approval, for ofatumumab (Arzerra) as a therapy for patients with chronic lymphocytic leukemia (CLL) who are refractory to fludarabine and alemtuzumab (Campath). (BioWorld International)